With Nextellis being the Gamechanger ? I just had a reread of...

With Nextellis being the Gamechanger ?
I just had a reread of past reports.
With 60m contraceptive pill prescriptions
written annually. Being $3.4b
Mayne had 3000+ in December 2021.
This from 0 June 21. Growth graph looks
good. Positive expansion.
I wouldn’t be surprised if 8000/ month attained
June 30 EOFY. This being 100,000 scripts/ annum.
Maynes outlook was 120,000/annum to achieve
2% market share by volume. This then amounting
to $200m / annum net sales.
All things being equal and few flys in the ointment.
These figures appear quite achievable EOFY 2023.
For any would be higher achieving investors too late
by then. As should Mayne be positive in all other
areas . International; Generic controls; Dermatology;
Womens Health; and their Metrics, Next months
report may well be the finally announced company
turnaround and true blue sky way forward. I really
believe Mayne is now a low risk high value BUY !!